drugset / Trial / NCT02182375

Effect of BI 201335 Mediated UGT1A1 (Uridine-diphosphate-glucuronosyltransferases) Inhibition in Healthy Volunteers

NCT02182375

Phase 1 Completed 24 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

Study to investigate the effect of UGT1A1 inhibition by single and multiple oral doses of BI 201335 on the single and multiple oral dose pharmacokinetics of raltegravir and to investigate safety and tolerability.

Timeline

Start
2010-01
Primary completion
2010-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Faldaprevir Small molecule 240 mg Oral
Subject Raltegravir Other / unclassified 400 mg Oral

Indications

No indication recorded.